JP7526783B2 - 癌を処置する方法 - Google Patents

癌を処置する方法 Download PDF

Info

Publication number
JP7526783B2
JP7526783B2 JP2022507799A JP2022507799A JP7526783B2 JP 7526783 B2 JP7526783 B2 JP 7526783B2 JP 2022507799 A JP2022507799 A JP 2022507799A JP 2022507799 A JP2022507799 A JP 2022507799A JP 7526783 B2 JP7526783 B2 JP 7526783B2
Authority
JP
Japan
Prior art keywords
acceptable salt
dose
pharma
cfg920
free base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022507799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543679A5 (enExample
JP2022543679A (ja
Inventor
ルー，クリス
ジャン，ルイポン
ユエ，ヨン
ジャン，ミンホア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laekna Ltd
Original Assignee
Laekna Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laekna Ltd filed Critical Laekna Ltd
Publication of JP2022543679A publication Critical patent/JP2022543679A/ja
Publication of JP2022543679A5 publication Critical patent/JP2022543679A5/ja
Application granted granted Critical
Publication of JP7526783B2 publication Critical patent/JP7526783B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022507799A 2019-08-08 2020-08-07 癌を処置する方法 Active JP7526783B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/099754 2019-08-08
CN2019099754 2019-08-08
PCT/US2020/045410 WO2021026454A1 (en) 2019-08-08 2020-08-07 Method of treating cancer

Publications (3)

Publication Number Publication Date
JP2022543679A JP2022543679A (ja) 2022-10-13
JP2022543679A5 JP2022543679A5 (enExample) 2023-08-10
JP7526783B2 true JP7526783B2 (ja) 2024-08-01

Family

ID=72234946

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022507799A Active JP7526783B2 (ja) 2019-08-08 2020-08-07 癌を処置する方法

Country Status (12)

Country Link
US (2) US20210038578A1 (enExample)
EP (1) EP4009969A1 (enExample)
JP (1) JP7526783B2 (enExample)
KR (1) KR20220047589A (enExample)
CN (1) CN114080225A (enExample)
AU (1) AU2020327022B2 (enExample)
BR (1) BR112022001508A2 (enExample)
CA (1) CA3148115A1 (enExample)
IL (1) IL289811A (enExample)
MX (1) MX2022001450A (enExample)
TW (1) TWI857119B (enExample)
WO (1) WO2021026454A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7010330B1 (en) 2003-03-01 2006-03-07 Theta Microelectronics, Inc. Power dissipation reduction in wireless transceivers
EP4438046A4 (en) * 2021-11-27 2025-12-03 Transthera Sciences Nanjing Inc NEW APPLICATION OF KINASE INHIBITOR
US20250177352A1 (en) 2022-03-14 2025-06-05 Laekna Limited Combination treatment for cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531884A (ja) 2013-10-01 2016-10-13 ノバルティス アーゲー 組合せ物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
ES2138618T3 (es) 1992-03-31 2000-01-16 Btg Int Ltd Esteroides 17-sustituidos utiles en el tratamiento del cancer.
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
BRPI0709771B1 (pt) 2006-03-27 2022-01-25 The Regents Of The University Of California Composto e composição farmacêutica
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
NZ594064A (en) * 2009-01-30 2012-08-31 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
PE20121048A1 (es) * 2009-06-26 2012-08-25 Novartis Ag Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
CA2872541A1 (en) * 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
CN108112235A (zh) * 2015-03-06 2018-06-01 克利夫兰临床基金会 改变类固醇代谢以用于治疗类固醇依赖性疾病

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531884A (ja) 2013-10-01 2016-10-13 ノバルティス アーゲー 組合せ物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Annals of Oncology，2016年，Vol.27, Suppl.6，VI243
Molecular Cancer Therapeutics，2015年，Vol.14, No.12, Suppl.2，B29
Steroids，2015年，Vol.95，p.80-87

Also Published As

Publication number Publication date
EP4009969A1 (en) 2022-06-15
TWI857119B (zh) 2024-10-01
AU2020327022B2 (en) 2025-12-18
US20250090514A1 (en) 2025-03-20
AU2020327022A1 (en) 2022-02-10
AU2020327022A8 (en) 2022-06-30
TW202120086A (zh) 2021-06-01
IL289811A (en) 2022-03-01
BR112022001508A2 (pt) 2022-07-12
CN114080225A (zh) 2022-02-22
JP2022543679A (ja) 2022-10-13
MX2022001450A (es) 2022-04-20
US20210038578A1 (en) 2021-02-11
KR20220047589A (ko) 2022-04-18
CA3148115A1 (en) 2021-02-11
WO2021026454A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
US20250090514A1 (en) Method of treating cancer
CN113164500A (zh) 治疗去势抵抗性和去势敏感性前列腺癌的方法
US20240180906A1 (en) Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer
EP2694074B1 (en) Use of a2b adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
US20210137890A1 (en) Deuterated imidazolidinedione compounds and their uses
EP3808345A1 (en) Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
TW202434251A (zh) 治療癌症之療法
EA049014B1 (ru) Способ лечения рака
US20250170146A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
EP4598520A1 (en) Methods of treating estrogen receptor-mediated disorders
WO2024076633A1 (en) Methods of treating estrogen receptor-mediated disorders
CA3269490A1 (en) Methods of treating estrogen receptor-mediated disorders
JP2026000999A (ja) 重度の肝障害を有する対象における非転移性去勢抵抗性前立腺癌の治療のためのアンドロゲン受容体阻害剤
WO2024015506A1 (en) Methods of treating estrogen receptor-mediated disorders
HK40098285A (en) Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
WO2023059714A1 (en) Methods of treating estrogen receptor-mediated disorders
HK40087811A (en) Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
CA3230285A1 (en) Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
TW202339748A (zh) 使用經取代之嘧啶-4(3h)-酮之治療方法
CN117098535A (zh) 用于治疗ddr基因突变转移性去势敏感性前列腺癌的他拉唑帕尼与抗雄激素的组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240625

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240722

R150 Certificate of patent or registration of utility model

Ref document number: 7526783

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150